Form 8-K - Current report:
SEC Accession No. 0001649094-25-000073
Filing Date
2025-05-07
Accepted
2025-05-07 16:03:56
Documents
15
Period of Report
2025-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcvx-20250507.htm   iXBRL 8-K 27249
2 EX-99.1 pcvx20250507-exx991.htm EX-99.1 68213
6 img251305552_0.jpg GRAPHIC 9918
  Complete submission text file 0001649094-25-000073.txt   247925

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pcvx-20250507.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pcvx-20250507_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pcvx-20250507_pre.xml EX-101.PRE 13046
17 EXTRACTED XBRL INSTANCE DOCUMENT pcvx-20250507_htm.xml XML 2908
Mailing Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39323 | Film No.: 25921180
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)